New startup ideas · Health and bio · Healthcare and bio
startup idea
Pulsefold
A $40 home panel clinics accept in place of a routine lab draw.
Pulsefold is a consumer countertop device with disposable cartridges that returns a cardiometabolic panel (lipids, HbA1c, kidney markers) in minutes at home, sold through pharmacy chains, employers and Medicare Advantage plans rather than direct.
- Hardware
- Consumer
- $100B+ market
- Collapses a cost 10x
- US first
3/5
venture judge
6
similar startups, last 2 years (16 all-time)
96%
of 3 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
76
Idea Score, 0-100 · raw 46.2 x 1.64
Active
competition: more crowded than 56% of ideas · headwind x0.72
+4.1
government priorities, secondary (50 matching grants)
Trend
54
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)23
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
72
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis100
- Moat axis100
- Neighbours still alive81
- Technologist judge50
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were home, panel, clinics, accept, place, routine, lab, draw.
The idea in full
- What
- Pulsefold is a consumer countertop device with disposable cartridges that returns a cardiometabolic panel (lipids, HbA1c, kidney markers) in minutes at home, sold through pharmacy chains, employers and Medicare Advantage plans rather than direct. The value is not the reading but acceptance: a clinician-facing result format that primary care practices agree to take as the pre-visit panel. Consumers buy cartridges on subscription; channel partners subsidize the hardware.
- Why now
- Carevision Inc. (500global 500G MENA 11) is building 60-second cardiometabolic screening as a staffed platform and Adialante (yc X26) is pushing screening past access barriers, which shows payers now buy screening throughput; 130 companies entered this cluster in the last two years and none of the recent cohort ships consumer-owned panel hardware.
- Wedge: first customer and entry point
- One large employer's diabetes management population: replace their quarterly draw-station visit with mailed cartridges, and get that employer's contracted clinic group to accept the result.
- Path to 100x
- US routine outpatient lab and primary care testing is a $100B+ market and a home cartridge takes a $200-400 draw-plus-visit down to tens of dollars. Acceptance is two-sided: every practice that accepts a Pulsefold panel makes the device more worth owning, and every owner pressures the next practice to accept it, which is how one result format wins the rail rather than five.
- Ceiling
- Clinicians refuse to act on unsupervised home samples, and the device settles into the wellness gadget shelf where consumers churn after two cartridges.
- Closest real companies, as the generator saw them
- Carevision Inc. runs a screening station model that needs an operator and a site; Pulsefold puts the cartridge in the home and monetizes recurring consumables. Lumius (yc X26) does accessible 3D ultrasound, a different modality with no consumables loop.
- Main risk
- Cartridge unit economics stay above $15 and the 10x cost story against a standard lab panel never materializes.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
Two-sided clinician acceptance could win the result rail, but capital-heavy cartridges above $15 kill the 10x story outright.
Bootstrapper
1/5
Cartridge manufacturing at sub-$15 unit cost plus payer and pharmacy channel deals needs far more than two-person capital.
Operator
2/5
Value depends entirely on primary care practices agreeing to accept an unsupervised home sample as the pre-visit panel.
Technologist
3/5
Consumer cartridge chemistry for HbA1c and lipids is genuine hardware work, but the stated blocker is unit cost above $15, not defensibility.
Risk
2/5
The value claim depends on clinicians accepting unsupervised home samples plus channel partners like Medicare Advantage plans, two gatekeepers it does not control.
trends
2/5
Home cardiometabolic panels were equally buildable in 2023 and the cited proof points are two screening startups, not a dated regulatory or platform shift.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (home, panel, clinics, accept, place, routine, lab, draw): 16 all-time, 6 from the last two years. Same matching as Idea Check.
A primary care clinic where AI earns clinical autonomy
Empowering next-gen precision oncology with scalable, in-house AI biomarkers from routine pathology slides.
Membership-based health platform for clinical testing, diagnostics and MRI scans
Candle helps friends and couples grow closer daily in just 5 minutes.
Klinrisk finds progressive kidney disease early before kidney function is lost
Memory Lane Games: Mayo Clinic-award winning dementia platform turning memories into engaging personalised quiz games for monitoring and management of cognitive decline.
Redcliffe Labs is India's Largest Omni-channel Diagnostics platform
API for at-home clinical sample collection.
Global at-home male fertility testing that delivers home comfort with lab accuracy — trusted by the world’s leading IVF clinics.
Operator of a software and logistics remote diagnostics company intended to offer at-home self-collected diagnostic testing services. The company integrates with clients so that they can offer at-home testing kits on behalf of patients to collect samples at home and send them back to partner labs, that are reviewed by licensed clinicians, thereby enabling customers to access remote diagnostics with secure infrastructure or preferred tech stack.
Online pets supplies for Latin America with over 4000 products & 20…
Rootine | Your Daily Health Routine, Smarter
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- AmblyoGo" a 'Smart' Easy-to-use Occlusion Dose Monitor (ODM) for Amblyopia in Childrenawardhigh relevance
NIH / NEI · SBIR phase II · $1M · posted 2026-08-10
- A novel remote blood separation device for at-home plasma collection for HIV-1 testingawardhigh relevance
NIH / NCHHSTP · SBIR phase II · $995K · posted 2025-09-30
NIH / NHLBI · SBIR phase II · $1M · posted 2026-08-10
- Developing a Learning Platform to Support Minimally Verbal Individuals with Autismawardhigh relevance
NIH / NIDCD · STTR phase I · $313K · posted 2026-07-01
- Home-based plasma self-collection device for remote diagnosis and monitoring of AD-associated biomarkersawardhigh relevance
NIH / NIA · SBIR phase I · $306K · posted 2025-09-25
- Development of an automated image enhancement system to improve point-of-care ultrasound imaging for out-of-hospital settingsawardhigh relevance
NIH / NIMHD · SBIR phase I · $337K · posted 2025-09-17
- Precise Wearable System for Accurate Continuous Gait Monitoring to Indicate Health Decline in Black Adults with Alzheimer's Disease and Related Dementiasawardhigh relevance
NIH / NIA · SBIR phase I · $500K · posted 2025-09-15
- HOMEals: A Science-Based Clinical Decision Support System for Nutrition in IDD Group Homesawardhigh relevance
NIH / NICHD · SBIR phase I · $385K · posted 2025-09-01
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Consumer
- Business model
- Hardware
- Path to 100x
- Collapses a cost 10x
- Market size
- $100B+ market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Real engineering
- Go-to-market
- Partners and channels
- Moat
- Network effects
- Geography
- US first
- Regulation
- Some regulation
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-23 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.